Letters Section Editor: Robert M. Golub, MD, Senior Editor.
To the Editor: The optimal duration of alendronate treatment is an important issue. In the FLEX study by Dr Black and colleagues,1 1099 women previously enrolled in the FIT trial who completed 5 years of alendronate were randomized to continue alendronate or to receive placebo for another 5 years. The overall fracture incidence was not different between the 2 groups, suggesting that alendronate discontinuation might be reasonable in most patients. This study raises a number of issues.
Delmas PD. Use of Alendronate After 5 Years of Treatment. JAMA. 2007;297(18):1979–1981. doi:10.1001/jama.297.18.1979-c
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: